- June 25, 2024: Inside the controversy over FDA’s recent gene therapy approval
- July 18, 2025: Analysts demand transparency after Sarepta’s roundabout disclosure of 3rd patient death
- July 18, 2025: FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths
- July 30, 2025: Prasad Resigns From Top FDA Post Amid Fallout Over Sarepta Dispute.
- August 7, 2025: The Sarepta Scandal: Laura Loomer, Vinay Prasad, and the history of pharma’s latest attempt to reassert control at Trump’s FDA
- November 3, 2025: Sarepta’s Duchenne confirmatory trial fails, but biotech will ask FDA for full approval anyway
All this for drugs that cost millions of dollars per dose from a company with $2B in revenue. Neutral people in the know have their opinions too. Know me by my enemies indeed.